JP2024531353A5 - - Google Patents
Info
- Publication number
- JP2024531353A5 JP2024531353A5 JP2024509458A JP2024509458A JP2024531353A5 JP 2024531353 A5 JP2024531353 A5 JP 2024531353A5 JP 2024509458 A JP2024509458 A JP 2024509458A JP 2024509458 A JP2024509458 A JP 2024509458A JP 2024531353 A5 JP2024531353 A5 JP 2024531353A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- pharmaceutical composition
- seq
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110988008.3 | 2021-08-26 | ||
| CN202110988008 | 2021-08-26 | ||
| PCT/CN2022/114652 WO2023025217A1 (zh) | 2021-08-26 | 2022-08-25 | 抗il4r抗体的药物组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024531353A JP2024531353A (ja) | 2024-08-29 |
| JP2024531353A5 true JP2024531353A5 (https=) | 2025-08-22 |
Family
ID=85321561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024509458A Pending JP2024531353A (ja) | 2021-08-26 | 2022-08-25 | 抗ｉｌ４ｒ抗体の医薬組成物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240343815A1 (https=) |
| EP (1) | EP4393506A4 (https=) |
| JP (1) | JP2024531353A (https=) |
| KR (1) | KR20240053586A (https=) |
| CN (2) | CN119174816A (https=) |
| IL (1) | IL310427A (https=) |
| TW (1) | TW202313692A (https=) |
| WO (1) | WO2023025217A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121889167A (zh) * | 2023-09-13 | 2026-04-17 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
| CN118105485B (zh) * | 2024-04-26 | 2024-09-03 | 湖南麦济生物技术有限公司 | 一种稳定的抗人IL-4Rα单克隆抗体制剂 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| MY149079A (en) * | 2006-10-02 | 2013-07-15 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor |
| CN101600456A (zh) * | 2006-12-11 | 2009-12-09 | 惠氏公司 | 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物 |
| WO2009121847A2 (en) * | 2008-04-02 | 2009-10-08 | Apogenix Gmbh | Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders |
| NZ609557A (en) * | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| CN108409860B (zh) * | 2017-02-10 | 2021-10-15 | 三生国健药业（上海）股份有限公司 | 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用 |
| BR112022017174A2 (pt) * | 2020-02-27 | 2022-10-18 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor |
| CN111961651B (zh) * | 2020-07-02 | 2023-05-23 | 北京佳德和细胞治疗技术有限公司 | 基因重组PD-1抗体自分泌型人γδT细胞及其构建方法和应用 |
-
2022
- 2022-08-25 TW TW111132100A patent/TW202313692A/zh unknown
- 2022-08-25 US US18/293,838 patent/US20240343815A1/en active Pending
- 2022-08-25 IL IL310427A patent/IL310427A/en unknown
- 2022-08-25 JP JP2024509458A patent/JP2024531353A/ja active Pending
- 2022-08-25 EP EP22860563.0A patent/EP4393506A4/en active Pending
- 2022-08-25 WO PCT/CN2022/114652 patent/WO2023025217A1/zh not_active Ceased
- 2022-08-25 CN CN202411571032.7A patent/CN119174816A/zh active Pending
- 2022-08-25 CN CN202280046126.5A patent/CN117615785A/zh active Pending
- 2022-08-25 KR KR1020247006591A patent/KR20240053586A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11932688B2 (en) | Treatment for neoplastic diseases | |
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| JP2020518599A5 (https=) | ||
| JP2016515511A5 (https=) | ||
| JP2013165711A5 (https=) | ||
| JP2014522843A5 (https=) | ||
| JP2020521797A5 (https=) | ||
| JP2020509027A5 (https=) | ||
| JP2023507190A5 (https=) | ||
| TW200815029A (en) | Anti-IGF-1R human monoclonal antibody formulation | |
| JP2024531353A5 (https=) | ||
| RU2021130306A (ru) | Композиции il-12, нацеленные на edb | |
| CN111356476A (zh) | Lag-3抗体药物组合物及其用途 | |
| JP2025128343A5 (https=) | ||
| RU2012131411A (ru) | АНТИТЕЛА ПРОТИВ Bv8 И ИХ ПРИМЕНЕНИЕ | |
| WO2025103379A1 (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| CN111683681A (zh) | 包含抗ox40抗体的制剂、其制备方法及其用途 | |
| JP2024505128A5 (https=) | ||
| WO2026046060A1 (zh) | 抗b7h3抗体药物偶联物用于治疗癌症的方法 | |
| WO2026017820A1 (en) | Fusion protein for cancer treatment | |
| HK40002544A (en) | Treatment for neoplastic diseases | |
| HK40002544B (en) | Treatment for neoplastic diseases | |
| JP2024511831A5 (https=) | ||
| WO2019195090A1 (en) | Ramucirumab for the treatment of cancers in pediatric patients | |
| HK1229696B (en) | Treatment for neoplastic diseases |